The direct in vitro tumor-killing and immune-mediated tumor cytotoxicity facilitated by PV001-DV contributes support of its upcoming clinical evaluation in patients with advanced melanoma who have failed prior therapy.
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases